Swing Therapeutics Seed

🏦 Potential exit path: M&A
Headquarters: San Francisco, California, United States
Category: Digital Therapeutics
Funding Amount: $9M
πŸ’Έ Last round was raised on August 11, 2021.
Select investors: JAZZ Venture Partners
Founded in 2019, Swing Therapeutics is developing digital treatments in disease areas where patients are not well-served. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company's near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.
πŸ‘₯ Key people:
⭐ Highlights:
  • Swing Therapeutics received FDA's Breakthrough Device Designation for its digital therapeutic for the management of fibromyalgia. πŸ”—
  • The company's experienced CEO has previously held senior positions at the genomic diagnostics company Veracyte. Before that, he worked at a VC firm and McKinsey.
  • The market for digital therapeutics is expected to reach $13.1 billion by 2026. πŸ”—
  • Swing Therapeutics could be an attractive acquisition target for a major pharmaceutical company looking to expand into digital therapeutics.
Last update: September 6, 2021